肾病个体中罕见线粒体DNA变异富集揭示未诊断的线粒体病
研究在27,747名MSM生物样本库参与者中评估mtDNA变异,发现肾病人群中临床相关mtDNA变异富集(OR=1.72),且42/45携带者既往无临床线粒体诊断。结果支持mtDNA分析在肾病评估中的价值。
要点
- 肾病人群中临床相关mtDNA变异富集,OR=1.72。
- 45名携带者中42人既往无临床线粒体诊断。
- 基因型-表型复核在14%未诊断携带者中发现一致表现。
核心结论
- 致病性mtDNA变异在肾病个体中过度代表,且常无已知线粒体诊断。
研究设计与样本
- 研究纳入MSM生物样本库27,747名参与者,具有全外显子测序和关联电子健康记录。
- 使用MitoVerse识别mtDNA变异,MITOMAP分类,肾脏病用肾PheCodes定义。
主要发现
- 3935名肾病个体中45人携带临床相关mtDNA变异,42人无既往临床线粒体诊断。
- mtDNA变异与肾脏受累风险增加相关(OR=1.72)。
- CKD(GU_582.2;OR=1.55)和肾衰竭(GU_582;OR=1.53)关联最强。
- 未诊断携带者中基因型-表型复核发现14%有一致表现,包括高尿酸血症性线粒体CKD。
- 变异水平分析发现MT-TV m.1630A>G富集(OR=5.56),其他变异呈趋势。
临床怎么用
- 对肾病尤其CKD或肾衰竭患者,可考虑mtDNA分析以识别未诊断线粒体病。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pathogenic mitochondrial DNA (mtDNA) variants cause multisystem disease, yet their contribution to kidney disease remains incompletely characterized, partly because of exclusion of the mitochondrial genome from genetic studies. METHODS: We evaluated mtDNA variation in 27,747 participants from the Mount Sinai Million Health Discoveries Program (MSM), an ancestrally diverse biobank with whole-exome sequencing and linked electronic health records (EHR). mtDNA variants were identified using MitoVerse and classified with MITOMAP. Kidney disease was defined using renal PheCodes for glomerular disease (GU_580) and renal failure (GU_582). Previous mitochondrial diagnoses were ascertained from EHR to identify undiagnosed individuals. Associations were adjusted for age, self-reported gender, and ancestry, with genotype-phenotype review. RESULTS: Among 3935 individuals with kidney disease, 45 carried clinically associated mtDNA variants, 42 of whom had no previous clinical mitochondrial diagnosis. mtDNA variants were enriched among individuals with kidney disease and associated with increased odds of renal involvement (odds ratio [OR] = 1.72). Associations were strongest for chronic kidney disease (CKD; GU_582.2; OR = 1.55) and renal failure (GU_582; OR = 1.53). Among undiagnosed carriers, genotype-phenotype review identified concordant manifestations in 14%, including mitochondrial CKD with hyperuricemia. Variant-level analysis identified enrichment of m.1630A>G in MT-TV (OR = 5.56), with additional variants showing trends. Both renal- and nonrenal-associated pathogenic mtDNA variants were observed. CONCLUSION: Pathogenic mtDNA variants are overrepresented among individuals with kidney disease, often without a known mitochondrial diagnosis. These findings support a contributory role for mtDNA in renal disease and highlight the value of mtDNA analysis into kidney disease research and clinical evaluation, particularly for identifying unrecognized mitochondrial disease with renal involvement.
引用
- Schecter DR, Tinker RJ, O'Connell P, et al. Enrichment of Rare Mitochondrial DNA Variants Among Individuals With Kidney Disease Reveals Undiagnosed Mitochondrial Disease. Kidney Int Rep. 2026. PMID: 42305255. doi:10.1016/j.ekir.2026.106578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。